{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:13:46Z","timestamp":1788257626146,"version":"build-2803163510"},"reference-count":54,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective is to review the potential impact of sphingosine-1-phosphate (S1P) receptor modulators on insulin resistance in patients with multiple sclerosis, including underlying mechanisms and clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>A literature search was conducted in PubMed for publications from inception through November 2025. Additional sources, including therapeutic positioning reports and official product information (Summary of Product Characteristics), were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Relevant English and Spanish language articles were extracted and evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Sphingosine-1-phosphate receptors (S1PR) regulate both immunological and metabolic functions, representing a key therapeutic target in multiple sclerosis. Agents such as fingolimod, siponimod, ozanimod and ponesimod bind to these receptors, thereby preventing lymphocyte migration into the central nervous system. Preclinical evidence suggests that S1P signaling participates in insulin receptor and Akt pathways, affecting glycogen synthesis, glucose uptake and \u03b2-cell survival. Clinical experience, including a case of a patient with type 1 diabetes and multiple sclerosis treated with ponesimod, indicates potential increases in insulin requirements and hyperglycemia, although formal human studies are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice:<\/jats:title>\n                    <jats:p>Clinicians should monitor glycemic control in patients with multiple sclerosis receiving S1PR modulators, especially those with pre-existing metabolic disorders. Awareness of potential insulin resistance may guide drug selection and metabolic management. Further prospective studies are warranted to clarify clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>S1PR modulators are effective disease-modifying therapies in multiple sclerosis, but emerging evidence suggests a possible impact on insulin signaling and glucose metabolism. Vigilance in metabolic monitoring is recommended, particularly in patients with diabetes or other risk factors for insulin resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251407146","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:20:41Z","timestamp":1767428441000},"page":"786-794","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4020-4892","authenticated-orcid":false,"given":"Sandra","family":"Ca\u00ed\u00f1a L\u00f3pez","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, University Hospital Complex of Pontevedra, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Mart\u00ednez Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, University Hospital Complex of Pontevedra, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bartolom\u00e9 Figueroa","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, University Hospital Complex of Pontevedra, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rodr\u00edguez Regal","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Complex of Pontevedra, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuarg.2012.05.002"},{"key":"e_1_3_2_3_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de Ponesimod (Ponvory\u00ae) en Esclerosis M\u00faltiple Recidivante [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2022. Accessed May 25 2025. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2022\/IPT_67-2022-Ponesimod.pdf"},{"key":"e_1_3_2_4_2","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda. La esclerosis m\u00faltiple afecta ya a m\u00e1s de 50.000 personas en Espa\u00f1a [in Spanish]. Published 2024. Accessed May 25 2025. https:\/\/www.sen.es\/saladeprensa\/pdf\/Link291.pdf"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.22201\/fesz.23958723e.2021.329"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020932"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.15761\/MRI.1000142"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.2855"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.268185"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.109959"},{"key":"e_1_3_2_11_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de Siponimod (Mayzent\u00ae) en Esclerosis M\u00faltiple Secundaria Progresiva [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2021. Accessed May 25 2025. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2021\/IPT_15-2021-Mayzent.pdf"},{"key":"e_1_3_2_12_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de Ozanimod (Zeposia\u00ae) en Esclerosis M\u00faltiple Remitente-Recurrente [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2022. Accessed May 25 2025. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2022\/IPT_65-2022-Zeposia.pdf"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000362990"},{"key":"e_1_3_2_14_2","unstructured":"Fundaci\u00f3n DiabetesCero. M\u00e1s all\u00e1 de la insulina. Parte 1: mapa de la diabetes tipo 1 en Espa\u00f1a [in Spanish]. Published 2024. Accessed May 25 2025. https:\/\/diabetescero.org\/wp-content\/uploads\/2024\/12\/Informe2024-MasAllaDeLaInsulina-Parte1-DiabetesCERO.pdf"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1440456"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1377601"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.28.061807.155530"},{"issue":"27","key":"e_1_3_2_18_2","first-page":"9","article-title":"Bases moleculares de las acciones de la insulina [in Spanish]","volume":"1","author":"Olivares Reyes JA","year":"2008","unstructured":"Olivares Reyes JA, Arellano Plancarte A. Bases moleculares de las acciones de la insulina [in Spanish]. Rev Educ Bioqu\u00edm. 2008;1(27):9-18.","journal-title":"Rev Educ Bioqu\u00edm"},{"key":"e_1_3_2_19_2","article-title":"Mecanismo de acci\u00f3n de la insulina [in Spanish]","volume":"72","author":"Gonz\u00e1lez-Mujica F.","year":"2017","unstructured":"Gonz\u00e1lez-Mujica F. Mecanismo de acci\u00f3n de la insulina [in Spanish]. Vitae Acad Biom\u00e9d Digit. 2017;72:1-12.","journal-title":"Vitae Acad Biom\u00e9d Digit"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0106-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.006"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1768"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3123-6"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.08.014"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2013.08.001"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102536"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0509"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S39564"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-016-1094-6"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-018-0134-x"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxq019"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-024-01347-2"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-020-0155-y"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.03.009"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12738"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0914-2"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102336"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"UpToDate. Drug interactions. Accessed November 13 2025. https:\/\/www.uptodate.com","DOI":"10.1097\/01.NPR.0000000000000303"},{"key":"e_1_3_2_39_2","unstructured":"DrugBank. Ponesimod. Accessed July 20 2025. https:\/\/go.drugbank.com\/drugs\/DB12016"},{"key":"e_1_3_2_40_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de Ponesimod (Ponvory\u00ae) [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2021. Accessed May 25 2025. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211550002\/FT_1211550002.html#10"},{"key":"e_1_3_2_41_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de Fingolimod (Gilenya\u00ae) [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2020. Accessed May 25 2025. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/11677005\/ft_11677005.html#10"},{"key":"e_1_3_2_42_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de Siponimod (Mayzent\u00ae) [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2020. Accessed May 25 2025. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1191414003\/FT_1191414003.html#10"},{"key":"e_1_3_2_43_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cnica de Ozanimod (Zeposia\u00ae) [in Spanish]. Ministerio de Sanidad Servicios Sociales e Igualdad; 2025. Accessed May 25 2025. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1201442001\/FT_1201442001.html#1"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70122"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795574"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0565-4"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52017"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-024-00699-2"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0814-1"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01431-8"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001397R"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2021.2021700"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30762"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3505"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.1001"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251407146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251407146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251407146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:21:05Z","timestamp":1788254465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251407146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/10600280251407146"],"URL":"https:\/\/doi.org\/10.1177\/10600280251407146","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}